Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/1995
08/15/1995CA1336715C 8-(4-piperidinyl)-4h-1-benzopyran-4-one derivatives and their use
08/15/1995CA1336691C Recombinant pseudomonas exotoxin: construction of an active immunotoxin with low side effects
08/10/1995WO1995021251A1 T-cell antigens, and their use in diagnosis and treatment of t-cell mediated conditions
08/10/1995WO1995021195A1 Non-viral vector
08/10/1995WO1995021194A1 Superactive vip antagonists
08/10/1995WO1995021180A1 Substituted lactose derivatives as cell adhesion inhibitors
08/10/1995WO1995021179A1 Endotoxin reduction or removal process
08/10/1995WO1995021177A1 Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
08/10/1995WO1995021175A1 Pharmaceutically active compounds and liposomes, and methods of use therof
08/10/1995WO1995021170A1 Antitumour tetracyclic compounds
08/10/1995WO1995020974A1 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides
08/10/1995WO1995020972A1 Treatment of ovarian estrogen dependent conditions
08/10/1995WO1995017876A3 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps
08/10/1995WO1995015373A3 Inhibition of dna methyltransferase
08/10/1995CA2182685A1 T-cell antigens, and their use in diagnosis and treatment of t-cell mediated conditions
08/10/1995CA2182616A1 Non-viral vector
08/10/1995CA2182485A1 Pharmaceutically active compounds and liposomes, and methods of use thereof
08/10/1995CA2182369A1 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides
08/10/1995CA2182361A1 Antitumour tetracyclic compounds
08/10/1995CA2182007A1 Substituted lactose derivatives as cell adhesion inhibitors
08/09/1995EP0666270A2 Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
08/09/1995EP0666252A1 Phenyl substituted alkyl carboxylic acid guanidines with perfluoroalkyl groups, process for their preparation, their use as medicament or diagnostic agent as well as medicament containing the same
08/09/1995EP0665752A1 Pharmaceutical compositions containing 3-beta-hydroxylated natural steroid derivatives, and use thereof
08/09/1995EP0665746A1 CONTROLLED-pH FORMULATION FOR INTRAVESICULAR INSTILLATION OF TGF$g(a)PE 40?ab
08/09/1995EP0579840B1 Fluorine-containing vitamin d3 analogues
08/09/1995EP0463152B1 Method of inhibiting angiogenesis of tumors
08/09/1995EP0461237B1 Use of 9,10-dihydrophenanthrene derivatives to prepare an antitumoral drug, and novel derivatives thereof
08/09/1995EP0348446B1 Antiviral antitumor antimetastatic immune system enhancing nucleosides and nucleotides
08/09/1995CN1106405A Trisubstituted pyrimido |5,4-d¨ pyrimidines for modulating
08/09/1995CN1106384A Vitamin D3-analogies
08/09/1995CN1106274A Anti-cancer capsule
08/09/1995CN1106269A Chinese herbs compn. for curing leukaemia and prepn. of cell regenerating decoction
08/09/1995CA2140379A1 Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus e7 oncoprotein
08/08/1995US5440056 Antitumor agents
08/08/1995US5440055 Method and apparatus for extracting taxol from source materials
08/08/1995US5440015 Selectin peptide medicaments for treating disease
08/08/1995US5439942 Method of treating certain tumors using illudin analogs
08/08/1995US5439936 Administering an acylfulvene anticarcinogenic agents, adjuvants with surgical or radiation therapy; side effect reduction
08/08/1995US5439921 Therapeutic use of piperidine-2,6-diones
08/08/1995US5439918 Inhibitors of farnesyl-protein transferase
08/08/1995US5439815 Restrictocin-like ribotoxin analogues comprising only one cysteine available for covalent linkage to a partner
08/08/1995US5439570 Water soluble texaphyrin metal complexes for singlet oxygen production
08/08/1995CA1336581C Aloe composition and uses thereof
08/08/1995CA1336578C Antiviral composition containing a hybrid _-interferon and its use
08/03/1995WO1995020678A1 Human dna mismatch repair proteins
08/03/1995WO1995020660A2 Immunization by inoculation of dna transcription unit
08/03/1995WO1995020656A1 Diagnosis of metastatic cancer by the mts-1 gene
08/03/1995WO1995020605A1 Immuno-stimulatory monoclonal antibodies
08/03/1995WO1995020600A1 Immunogens against gonadotropin releasing hormone
08/03/1995WO1995020582A1 Δ12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
08/03/1995WO1995020575A1 Aralkylamino substituted azacyclic therapeutic agents
08/03/1995WO1995020564A1 Leukotriene b4 derivatives, methods of preparing them and their use as drugs
08/03/1995WO1995020398A1 Human growth hormone
08/03/1995WO1995020396A1 Inhibitors of geranylgeranyl-protein transferase
08/03/1995WO1995020390A1 Use of vanadium molybdenum or tungsten complexes for controlling cellular proliferation
08/03/1995WO1995020320A1 Self-assembling multimeric nucleic acid constructs
08/03/1995WO1995012660A3 Recombinant p53 adenovirus methods and compositions
08/03/1995WO1995004720A3 Gastrin and cck receptor ligands
08/03/1995CA2182206A1 Human dna mismatch repair proteins
08/03/1995CA2182205A1 Human growth hormone
08/03/1995CA2181376A1 Aralkylamino substituted azacyclic therapeutic agents
08/03/1995CA2181062A1 Diagnosis of metastatic cancer by the mts-1 gene
08/03/1995CA2180528A1 Inhibitors of geranylgeranyl-protein transferase
08/03/1995CA2179715A1 Use of vanadium molybdenum or tungsten complexes for controlling cellular proliferation
08/03/1995CA2179176A1 .delta.12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them
08/02/1995EP0665289A2 Peptides from GAD65, provoking autoimmune reactions
08/02/1995EP0665020A2 Method for preparing thioether conjugates
08/02/1995EP0664819A1 Chelating polymers.
08/02/1995EP0664800A1 Novel taxane derivatives, their preparation and pharmaceutical compositions containing them
08/02/1995EP0664789A1 Inhibitors of farnesyl protein transferase
08/02/1995EP0664711A1 Peptide inhibitors of cellular adhesion
08/02/1995EP0664708A1 Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and an s-phase or m-phase specific antineoplastic agent
08/02/1995EP0664706A1 Protein kinase c inhibition and novel compound balanol
08/02/1995EP0664704A1 Use of dopamine agonists to activate gamma-interferon production
08/02/1995EP0664702A1 Tumoricidal activity of benzoquinonoid ansamycins against prostate cancer and primitive neural malignancies
08/02/1995EP0664700A1 Treatment of cachexia and inhibition of il-6 activity
08/02/1995CN1106016A Process of preparing etoposide phosphate and etoposide
08/02/1995CN1106006A Crystals of antimicrobial compound
08/02/1995CN1106005A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives
08/02/1995CN1106004A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives
08/02/1995CN1105967A Stilbene derivatives and carcinostatics containing them
08/02/1995CN1029400C Side chain homologe vitamin-D-derivatives, process for preparing same, pharmaceutical preparation containing same and use as medicine
08/01/1995US5438072 Taxoid-based compositions
08/01/1995US5438071 Stable porfimer sodium compositions and methods for their manufacture
08/01/1995US5438069 1,2-dideoxy-2-(hydroxymethyl)-1-(methylamino)-myo-inositol hydrochloride and stereoisomers; for treatment of viral infections and metastatic tumors
08/01/1995US5437951 A genetic construct comprising a PAPILLOMAVIRUS L1 gene; vaccines, diagnostic kits; genetic engineering
08/01/1995US5437866 Herbal treatment of malignancy
08/01/1995US5437865 Isolated sialylated glycoprotein endosialin, which is expressed by tumor associated vascular endothelium
08/01/1995CA1336506C Method for protection from chemotherapeutic side effects
08/01/1995CA1336497C Immunoconjugates for cancer diagnosis and therapy
07/1995
07/28/1995CA2141277A1 Method for preparing thioether conjugates
07/27/1995WO1995020045A1 Antibodies to egf receptor and their antitumour effect
07/27/1995WO1995019992A1 Compositions and methods using unbound mpl receptor for stimulating platelet production
07/27/1995WO1995019985A1 Haemopoietic maturation factor
07/27/1995WO1995019970A1 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
07/27/1995WO1995019965A1 Synthetic matrix metalloprotease inhibitors and uses thereof
07/27/1995WO1995019961A1 Metalloproteinase inhibitors
07/27/1995WO1995019957A1 Hydroxamic acid derivatives as metalloproteinase inhibitors
07/27/1995WO1995019956A1 Metalloproteinase inhibitors
07/27/1995WO1995019841A1 Particulate material
1 ... 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 ... 2211